Incyte Corporation (INCY), BioMarin Pharmaceutical Inc. (BMRN): Two Biotech Stocks That Could Be on Novartis AG (ADR) (NVS)’s Buyout Radar

Page 1 of 2

Novartis AG (ADR) (NYSE:NVS)The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is really beginning to heat up, and it’s offering investors an in-their-face reminder that rapid growth and a promising pipeline are rare and come only for a high price in the health care industry.

Amgen originally offered to purchase Onyx for $120 per share almost seven weeks ago, but quickly found that offered rebuffed by Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), who was intent on shopping itself around and holding out for a better price. With Amgen now upping its offer to $9.5 billion, or $130 per share, some of the more serious bidders are beginning to bow out of the fray.

One of the potential bidders that have decided to step aside is oncology and hematology powerhouse Novartis AG (ADR) (NYSE:NVS). According to a Bloomberg report, Novartis AG (ADR) (NYSE:NVS) chairman Joerg Reinhardt is capping any future acquisition target at $10 billion, but he has no interest in acquiring Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) at such a steep price. That doesn’t, however, mean Novartis AG (ADR) (NYSE:NVS) isn’t on the prowl.

Source: Andrew Hecht, Flickr.

Novartis on the prowl
Novartis AG (ADR) (NYSE:NVS) is certainly no stranger to the dangers of the patent cliff. Like many of the world’s largest pharmaceutical companies, it’s seen some of its biggest money-making drugs fall victim to generic competition. Last year saw the loss of high blood pressure medication Diovan, which had contributed $5.7 billion (about 10% of annual sales) in revenue in 2011, and breast cancer medication Femara. Looking ahead to next year, its blockbuster leukemia treatment Gleevec will lose its patent exclusivity.

New drugs are helping to curtail this steep revenue drop-off, including relapse-remitting multiple sclerosis drug Gilenya, which saw sales rise 66% in the second quarter over the year-ago period, and kidney cancer drug Afinitor, which delivered a 77% spike in sales. But, there’s still nothing that can turn around an ailing pipeline quicker than an earnings-accretive acquisition.

Two companies on the radar
Here are two companies that I feel would be a good fit for Novartis AG (ADR) (NYSE:NVS).

Incyte Corporation (NASDAQ:INCY) – current market cap, $4.18 billion.
Incyte Corporation (NASDAQ:INCY) would make a lot of sense as a potential buy candidate for Novartis AG (ADR) (NYSE:NVS) given that the two companies already have an ongoing licensing pact with FDA-approved myelofibrosis drug Jakafi. Under the current deal, Incyte Corporation (NASDAQ:INCY) has the rights to Jakafi within the U.S. with Novartis claiming worldwide rights to the drug everywhere else. Jakafi (known as ruxolitinib in testing) is also being studied as a treatment for polycythemia vera, pancreatic cancer, and solid/hematologic tumors.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!